PROJECTS
>>Ramp up of Product Development Efficiencies
>>Transformation through In-Licensing & Site Transfers
>>Out-License of New Molecular Entity by Biotech Footprint Late
>>Strengthening of Overseas Footprint
>>Divestment of Late Life Cycle Products
>>Commercializing a Reformulated Product
>>Business Development for Development Stage Enabling Technology
>>Restructuring Clinical Operations
>>Optimal Drug Development Path and Licensing Process
>>Post-Merger integration of Research and Development operations
Divestment of Late Life Cycle Products
A large multinational pharmaceutical company decided to more diligently manage the late life cycle products in its portfolio, and to divest such products at a point when sales had begun to decline and sales resources had been reassigned to other products. This company had worked previously with Garphi, when the company had out-licensed a product to a client of Garphi. The company requested Garphi to manage the divestment project for them. Garphi prepared the Information Memorandums, identified appropriate targets, generated competition for the asset, assisted with buyers’ due diligence investigation, and finally the negotiation of the definitive agreement. As a result of the controlled auction process utilized by Garphi, the company received a better deal for its assets. They have since retained Garphi to manage additional divestment assignments.
